EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

A case of complete remission by cabozantinib as an end-line treatment for advanced hepatocellular carcinoma

Shuhei Nagashima, Satoshi Kobayashi, Shotaro Tsunoda, Yui Yamachika, Yuichiro Tozuka, Taito Fukushima, Manabu Morimoto, Makoto Ueno, Junji Furuse, Shin Maeda

Clinical Journal of Gastroenterology · 2025

DOI: 10.1007/s12328-024-02062-2 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Journal of Gastroenterology, 2025. Verfasst von Shuhei Nagashima und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, 241-8515, Japan. shuhei.nagashima@gmail.com. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Anilides, Pyridines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cabozantinib is a multi-kinase inhibitor targeting multiple tyrosine kinases. It improves overall survival and progression-free survival in patients previously treated with sorafenib for advanced hepatocellular carcinoma (HCC) compared to the placebo in the phase 3 CELESTIAL trial. A 71-year-old man presented to our hospital for treatment of HCC with chronic hepatitis C. He was refractory to sorafenib, lenvatinib, regorafenib, and ramucirumab and started atezolizumab and bevacizumab therapy in November 2020. After administering the second cycle on December 10, 2020, the patient was diagnosed with progressive disease in January 2021. Therefore, cabozantinib (60 mg/day) was initiated on January 14, 2021. As the grade 3 aspartate aminotransferase and alanine aminotransferase levels increased, grade 3 anorexia and a decline in performance status were observed in the first week, and cabozantinib was terminated. His performance status and anorexia gradually improved, and contrast-enhanced computed tomography (CT) in June 2021 showed complete remission (CR) according to the modified Response Evaluation Criteria in Solid Tumors. The patient did not show disease progression for 11 months without receiving any treatment for HCC. To the best of our knowledge, this is the first report of CR with cabozantinib in advanced HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAnilidesPyridinesProtein Kinase InhibitorsAntineoplastic AgentsHumansMaleAgedRemission Induction

Stichwörter der Autor:innen

CabozantinibComplete remissionHepatocellular carcinomaImmune checkpoint inhibitor

Substanzen

cabozantinibAnilidesPyridinesProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, 241-8515, Japan. shuhei.nagashima@gmail.com.
  • Department of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan. shuhei.nagashima@gmail.com.
  • Department of Gastroenterology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, 241-8515, Japan.
  • Department of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.

Zitieren

APA

Nagashima, S., Kobayashi, S., Tsunoda, S., Yamachika, Y., Tozuka, Y., Fukushima, T., Morimoto, M., Ueno, M., Furuse, J., & Maeda, S. (2025). A case of complete remission by cabozantinib as an end-line treatment for advanced hepatocellular carcinoma. Clinical Journal of Gastroenterology. https://doi.org/10.1007/s12328-024-02062-2

Vancouver

Nagashima S, Kobayashi S, Tsunoda S, Yamachika Y, Tozuka Y, Fukushima T, et al. A case of complete remission by cabozantinib as an end-line treatment for advanced hepatocellular carcinoma. Clinical Journal of Gastroenterology. 2025. doi:10.1007/s12328-024-02062-2

BibTeX
@article{Nagashima2025,
  author = {Nagashima, Shuhei and Kobayashi, Satoshi and Tsunoda, Shotaro and Yamachika, Yui and Tozuka, Yuichiro and Fukushima, Taito and Morimoto, Manabu and Ueno, Makoto and Furuse, Junji and Maeda, Shin},
  title = {A case of complete remission by cabozantinib as an end-line treatment for advanced hepatocellular carcinoma},
  journal = {Clinical Journal of Gastroenterology},
  year = {2025},
  doi = {10.1007/s12328-024-02062-2}
}
Kostenlos starten →